IL17A and colitis: Like IL-17 blockade, treatment with a neutralising anti-IL-22 mAb had no effect on systemic disease or colitis in the proximal colon (Figure 1A&B), indicating that in our facility, IL-22 is also redundant for disease induction in this model.